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ABSTRACT
Objectives: To compare outcomes and cost-
effectiveness of various initial imaging strategies in the
management of stable chest pain in a long-term
prospective randomised trial.
Setting: Regional cardiothoracic referral centre in the
east of England.
Participants: 898 patients (69% man) entered the
study with 869 alive at 2 years of follow-up. Patients
were included if they presented for assessment of
stable chest pain with a positive exercise test and no
prior history of ischaemic heart disease. Exclusion
criteria were recent infarction, unstable symptoms or
any contraindication to stress MRI.
Primary outcome measures: The primary
outcomes of this follow-up study were survival up to a
minimum of 2 years post-treatment, quality-adjusted
survival and cost-utility of each strategy.
Results: 898 patients were randomised. Compared
with angiography, mortality was marginally higher in
the groups randomised to cardiac MR (HR 2.6, 95% CI
1.1 to 6.2), but similar in the single photon emission
CT-methoxyisobutylisonitrile (SPECT-MIBI; HR 1.0,
95% CI 0.4 to 2.9) and ECHO groups (HR 1.6, 95% CI
0.6 to 4.0). Although SPECT-MIBI was marginally
superior to other non-invasive tests there were no
other significant differences between the groups in
mortality, quality-adjusted survival or costs.
Conclusions: Non-invasive cardiac imaging can be
used safely as the initial diagnostic test to diagnose
coronary artery disease without adverse effects on
patient outcomes or increased costs, relative to
angiography. These results should be interpreted in the
context of recent advances in imaging technology.
Trial registration: ISRCTN 47108462, UKCRN 3696.
INTRODUCTION
Coronary artery disease (CAD) is common
and its management is costly.1
Revascularisation using bypass surgery (cor-
onary artery bypass graft, CABG) or percu-
taneous coronary intervention (PCI) is
effective for patients with severe disease2 but
a signiﬁcant minority of patients do not gain
symptomatic relief.3 Data from the Clinical
Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE)
trial did not show prognostic beneﬁts from
revascularisation in any patient subgroup.4
The yield of coronary angiography (CA) is
variable with one recent large study of nearly
400 000 patients demonstrating a normalcy
rate approaching 40%.5 Therefore non-
invasive testing to identify those with a low
likelihood of obstructive CAD may be safer,
Strengths and limitations of this study
▪ This is the only large randomised prospective
trial of a strategy of non-invasive gate-keeper
cardiac imaging versus upfront angiography in
the literature.
▪ This is one of only very few comparative effect-
iveness studies in cardiac imaging to include
data on stress perfusion cardiac magnetic reson-
ance imaging.
▪ The cost-utility data are derived from National
Health Service tariffs and our results are not
necessarily directly transferrable to other health-
care systems.
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cheaper and more appropriate than upfront angiog-
raphy. This approach is codiﬁed in multiple American
Heart Association/American College of Cardiology
(AHA/ACC) guidelines on the investigation of stable or
suspected angina pectoris in which initial non-invasive
imaging is rated as highly appropriate.6–9
The ‘Cost-Effectiveness of non-invasive Cardiac Testing’
(CECaT) trial was an unblinded non-inferiority trial
designed to assess three functional tests—stress echocar-
diography, single photon emission CT (SPECT) and
stress cardiac MR (CMR)—as a gate-keeper to CA in
patients referred for CA with suspected CAD. Early clin-
ical and cost-effectiveness estimates have been published
and showed that the CMR group had slightly lower
mean exercise treadmill time according to the Bruce
protocol but otherwise the tests could be considered
equally effective.10 This report provides the main cost-
effectiveness and mortality outcomes up to 6 years after
randomisation.
METHODS
Study design
The design of the study has been described elsewhere10
and is reviewed brieﬂy here. All patients referred to
Papworth Hospital, UK for non-urgent angiography
were eligible for the study. Inclusion criteria were: estab-
lished or suspected chronic stable angina and a positive
exercise tolerance test result with subsequent referral for
angiography. Exclusion criteria were: recent MI (<3
months), revascularisation (<6 months); urgent need for
revascularisation; contraindication to adenosine or
CMR; inability to exercise.
Trial design was of four parallel arms with a 1:1:1:1 ran-
domisation ratio. Randomisation was computer gener-
ated and stratiﬁed according to Pryor risk assessment.11
Within each Pryor risk group, randomisation was in
blocks of length 6 or 8. Sequentially numbered group
designation was held in the research and development
(R&D) ofﬁce and was not available to trial personnel.
Patients were randomised to their initial diagnostic test—
stress SPECT, stress CMR, stress echocardiography or
angiography—by R&D within 4 weeks of recruitment and
only after they had given consent and been registered.
Non-invasive imaging results were returned with a rec-
ommendation to proceed with angiography only when
reported as ‘positive’ for inducible ischaemia. Protocol
adherence to this recommendation was not mandated
by trial design and patients proceeded to angiography if
considered clinically indicated. Treatment with PCI or
CABG (performed within 6 months of angiography) or
medical therapy was according to standard practice.
Coronary angiography
Standard diagnostic angiography was performed from
the right femoral artery approach.12 A minimum of ﬁve
views of the left and three views of the right coronary
system were taken.13 All examinations were reported by
an experienced staff cardiologist and segmental location
of disease (if any) was recorded.
Stress echocardiography
β-Blocker medications were stopped 2 days beforehand.
Dobutamine was infused at rates of 10–40 µg/kg/min,
increased at 3 min intervals. If necessary, 300–600 μg of
atropine were added at peak stress to achieve 90% of
target heart rate. Images were acquired in standard
planes in the ﬁnal minute of each 3 min stage.
Intravenous microspheres were used to delineate the
endocardial surface. All examinations were reported by
one of two staff cardiologists experienced in stress echo-
cardiography. Studies were positive for ischaemia if
stress-induced deterioration in contractility was observed.
SPECT
Rest/stress 99mTc sestamibi (99mTc MIBI) SPECT was
performed (2 day protocol). A 6 min adenosine infusion
(140 g/kg/min) was employed. 400 MBq 99m-Tc MIBI
was administered at 3 min after infusion of adenosine
was started. Gated SPECT imaging occurred 60 min
after injection. Tomographic images were assessed for
ﬁxed and reversible defects by a single observer (as per
established criteria).14
CMR
Stress CMR was performed at a standard similar to that
which was subsequently recommended by the Society of
CMR.15 A 1.5 T mobile CMR system and four-channel
phased array surface coil were used (Signa CV/i, GE
Medical Systems). Stress/rest dynamic ﬁrst-pass perfusion
imaging was performed. A hybrid fast gradient ECHO/
echoplanar sequence was employed.16 Adenosine was
infused at 140 µg/kg/min for 4 min. After 3 min, a bolus
of gadolinium-diethylenetriaminepenta acetic acid
(0.1 mmol/kg) was delivered at 5 mL/s, followed by a
25 mL saline ﬂush. First-pass imaging of the heart
occurred over 80 heart beats. A volumetric notched-
saturation prepulse preserved a constant saturation-
recovery time during slice acquisition.17 Six to eight short
axis slices were obtained every two heart beats. Rest
imaging was repeated after a minimum interval of
15 min. Cine steady state free precession images and late
gadolinium enhancement images were also acquired as
described in the original CECaT protocol.10 Studies were
reported as positive if there was an inducible perfusion
defect visible for at least ﬁve frames either: (1) in a
region of normal wall thickness or (2) in a region of myo-
cardial thinning in the absence of a history of prior myo-
cardial infarction (MI).
Outcomes
The primary outcome in the original CECaT trial was
exercise treadmill time at 18 months postrandomisation
using the modiﬁed Bruce protocol, in which exercise
intensity was increased every 3 min. There was a range of
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secondary outcomes including diagnostic accuracy, clin-
ical events, health-related quality and cost-effectiveness of
life up to 18 months after randomisation.10
The primary outcomes of this follow-up study were sur-
vival up to a minimum of 2 years post-treatment,
quality-adjusted survival and cost-utility of each strategy.
Survival status at the end of follow-up was determined
from the Ofﬁce for National Statistics database, UK
(http://www.ons.gov.uk/).
Quality of life was measured using the EuroQoL
EQ-5D questionnaire18 which was completed at baseline,
6 and 18 months postrandomisation, and at 6, 18 and
24 months post-treatment. The social tariff for the
EQ-5D was applied in order to calculate utility values.19
Because post-treatment measurements were at variable
times postrandomisation (randomisation date is time zero
for a randomised trial) daily utilities were estimated
using linear interpolation.
Sample size calculations
The sample size of 898 patients was based on exercise
performance and was calculated according to the meth-
odology published in the initial report of the CECaT
study.10
Statistical and economic analysis
For this study, survival was summarised using
Kaplan-Meier estimates and the groups were compared
using Cox proportional hazards regression. This assumes
that the instantaneous risk of death (hazard) for a refer-
ence value of a covariate will vary through time, but that
the hazards for other values of the covariate will be a
constant multiple of this baseline hazard, and this mul-
tiple will not vary through time. This assumption was
tested using Schoenfeld residuals and there was little evi-
dence against it. The diagnostic test was entered into the
Cox regression as a four-level ﬁxed covariate, with angi-
ography as the reference category. In sensitivity analysis
CABG and PCI were included in the regression analyses
as time-varying covariates, taking a value 0 up to the
time of intervention and 1 thereafter, to ensure that any
differences between the groups was not due to differ-
ences in treatment. Inclusion of treatment (CABG/PCI)
did not affect comparison of diagnostic strategies and
results of these analyses are not included here.
Patient-speciﬁc hospital resource use was collected for
2 years post-treatment with revascularisation or medical
management. Costs were based on National Health
Service reference costs 2005/2006 prices. An annual dis-
count rate of 3.5% was applied to all costs and
quality-adjusted life-years (QALYs) after 12 months post-
randomisation. Resources costed were: imaging tests;
revascularisation; inpatient/outpatient episodes; adverse
events; cardiac-related medications. Patient-reported
admissions for MI were veriﬁed with the admitting hos-
pital and adjudicated.
Quality-adjusted survival and cost-estimates were cen-
sored at the last follow-up at 2 years after treatment,
resulting in varying duration of follow-up from the time
of randomisation to the different diagnostic strategies,
so that mean values over a range of time horizons were
estimated using inverse weighting methods.20 This
method allows for differing follow-up times between
patients by splitting follow-up time into intervals, and
up-weighting the observed quality-adjusted survival and
costs in an interval in proportion to the inverse of the
Kaplan-Meier estimate of the proportion observed
during the interval. In the base case we used a time
horizon of 3 years since it was the longest period over
which results were stable, with acceptable precision. CIs
for costs and QALYs were estimated using bootstrapping
with 5000 samples.21
Sensitivity analysis
Sensitivity of cost-utility results for different time hori-
zons was assessed by re-estimating results up to 12, 18,
24, 36 and 48 months after randomisation. In addition,
cardiologists were divided into those who did and did
not perform PCI as part of their routine clinical prac-
tice, and the results were recalculated for each sub-
group. With the exception of this post hoc data
interrogation, all other results presented derive from the
intention-to-treat analysis.
The study had Institutional Review Board (IRB)
approval and full written informed consent was obtained
from all participants. All authors had full access to the
data and take responsibility for the manuscript as
written.
RESULTS
Recruitment and compliance
Between September 2001 and September 2004, 3201
patients were assessed, 1981 were excluded and 322
refused entry to the trial. Refusals were more likely to
come from women (46% compared with 31% enrolled
into the study, p<0.001) and were signiﬁcantly older
(mean age 64.6, (SD 10.1) compared with study group
mean age 61.8, (9.4), p<0.001).
In total 898 patients were randomised. Groups were
well matched at baseline (table 1). In each group 69%
of patients were high risk for CAD (Pryor score >0.8).
The trial was closed to recruitment in September 2004
after enrolling the prespeciﬁed number of participants.
One hundred and seventy-ﬁve (78%) SPECT patients,
180 (80%) CMR patients and 169 (75%) stress ECHO
patients were referred on for angiography (ﬁgure 1).
Between 20% and 25% of patients undergoing non-
invasive tests did not require further investigation.
Twenty-one per cent of patients who had negative tests
were referred for angiography and the proportion was
similar in each group (SPECT n=45, CMR n=50, ECHO
n=48, p=0.858). Of these 14 (31%) SPECT, 26 (52%)
CMR and 23 (48%) ECHO resulted in a positive angio-
gram (p=0.130). Four patients died and four withdrew
from the trial early on. Of the remaining patients,
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revascularisation was required in 34% (301/890—see
ﬁgure 1 for numbers in each arm). There was no signiﬁ-
cant difference between the groups in initial patient
management (ﬁgure 1; p=0.527). Beyond the initial
management strategy 42 subsequent revascularisation
procedures were required in the angiography arm com-
pared with 30 in the SPECT, 44 in the CMR and 41 in
the ECHO arms. The median times between randomisa-
tion and initial revascularisation were 122 days in the
angiography group, 192 days for SPECT, 184 days for
CMR and 177.5 days for ECHO, resulting in a delay due
to functional testing of approximately 2 months.
Survival
During the study there were 7 (3%), 7 (3%), 18 (8%)
and 11 (5%) deaths in the angiography, SPECT, CMR
and ECHO groups respectively. Kaplan-Meier survival
curves for the four groups are plotted in ﬁgure 2.
Survival over the whole trial period in the SPECT (HR
1.0, 95% CI 0.4 to 2.9) and stress ECHO (HR 1.6, 95%
CI 0.6 to 4.0) groups were not signiﬁcantly different
from angiography but the CMR group had higher mor-
tality, with HR 2.6 (95% CI 1.1 to 6.2), p=0.032. The sig-
niﬁcant effect of CMR on survival remained when
CABG or PCI were included in the models. However,
mortality was low in all groups and the absolute mean
difference in survival was less than 1 month over 3 years
(table 2). Mean survival estimates over 3 years with 95%
Cls are shown in table 2.
All patients had complete adverse event data up to
18 months postrandomisation during which there were
178 non-fatal adverse events in 114 patients, mostly hos-
pital admissions for chest pain (table 3). Beyond this
time only adverse events that resulted in admissions were
recorded as they were relevant for the economic ana-
lysis. No patient suffered any adverse event at the time
of the initial randomised imaging test.
Cost-utility
Table 4 shows some of the highest incurred follow-up
costs for the four groups and shows that patient manage-
ment varied substantially between individuals. Although
angiography was the most expensive of the four initial
diagnostic tests, the strategy of initial angiography had
lower mean overall cost than stress ECHO, and was
similar to CMR up to 3 years (table 2). Extra costs for
patients in the three non-invasive groups were largely
due to patients undergoing follow on angiography.
Table 1 Baseline characteristics*
Demographics
Angiography
(n=222)
SPECT
(n=224)
Cardiac MRI
(n=226)
Stress ECHO
(n=226)
Mean (SD) age (years) 60.7 (9.1) 62.1 (9.5) 62.2 (9.0) 61.9 (9.9)
Males (%) 149 (67%) 157 (70%) 153 (68%) 160 (71%)
History/risk factors
Previous MI (%) 63 (28%) 52 (23%) 69 (31%) 59 (26%)
Previous CVA (%) 10 (5%) 13 (6%) 8 (4%) 12 (5%)
Diabetes (%)
IDDM 12 (5%) 8 (4%) 11 (5%) 5 (2%)
NIDDM 16 (7%) 18 (8%) 21 (9%) 22 (10%)
Family history CAD 60 (27%) 55 (25%) 63 (28%) 59 (26%)
Smoking history (%)
<25 pack-years 149 (67%) 162 (72%) 148 (65%) 155 (69%)
≥25 pack-years 73 (33%) 62 (28%) 78 (35%) 71 (31%)
Treated hyperlipidaemia (%) 164 (74%) 171 (76%) 179 (79%) 179 (79%)
Treated hypertension (%) 117 (53%) 132 (59%) 115 (51%) 129 (57%)
Exercise tolerance using the modified Bruce protocol
Mean (SD) total exercise time (min) 11.29 (4.56) 10.46 (4.41) 10.43 (4.43) 10.89 (4.36)
ECG changes on exercise test
1–2 mm ST depression with
symptoms
53 (24%) 43 (19%) 54 (24%) 57 (25%)
≥2 mm ST depression without
symptoms
16 (7%) 24 (11%) 20 (9%) 24 (11%)
ST elevation†/no change 153 (69%) 157 (70%) 152 (67%) 145 (64%)
CCS class
0–I 60 (27%) 54 (24%) 78 (35%) 58 (26%)
II 138 (62%) 144 (64%) 122 (54%) 132 (58%)
III–IV 24 (11%) 26 (12%) 26 (11%) 36 (16%)
*There were no significant differences between the groups in any variable.
†ST elevation was observed in three angiography, two CMR and one ECHO patients.
CAD, coronary artery disease; CCS, Canadian Cardiovascular Society CVA; cerebrovascular accident; IDDM, Insulin-dependent diabetes
mellitus; MI, myocardial infarction; NIDDM, non-insulin-dependent diabetes mellitus; SPECT, single photon emission CT.
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There were no signiﬁcant differences in overall costs
between the groups.
During the study there were no signiﬁcant differences
in EQ-5D between the groups. Figure 3 shows daily mean
EQ-5D utility over time based on interpolation between
measurements for survivors who completed the EQ-5D.
Using inverse-weighting we calculated QALYs over differ-
ent time horizons and these are presented up to 3 years
in table 2. Mean QALYs over 3 years in the angiography
group was 2.24, which was not signiﬁcantly different from
the other groups. Figure 4 shows the joint distribution of
the difference in mean cost against the difference in
mean QALY for each diagnostic strategy group and angi-
ography alone, and shows the uncertainty in these esti-
mates. Figure 5 shows the cost-effectiveness acceptability
curve and demonstrated that SPECT has a high chance
(>70%) of being cost-effective whatever the willingness-
to-pay threshold is but for CMR and ECHO there is
much less certainty about this decision. The mean differ-
ences between groups were close to zero in all three cases
so that the cost-per-QALY estimates are unstable and a
cost-minimisation approach may be more appropriate.
This would favour SPECT, which was both cheaper and
more effective on average than angiography, and had the
lowest overall cost.
Sensitivity analysis
The comparisons between the diagnostic strategy groups
did not change substantially when we varied the time
horizon; the main effect of this was that the variation
Figure 1 CONSORT diagram describing recruitment and randomisation.
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surrounding estimates increased as the time horizon
lengthened due to the heavy censoring (results not
shown). Tables 5 and 6 show results for interventional
and non-invasive cardiologists respectively. Patients who
were managed by interventional cardiologists incurred
higher costs due to the greater number of tests and
revascularisation procedures performed, with minimal
incremental beneﬁt in QALY.
DISCUSSION
CECaT is the ﬁrst completed prospective randomised
trial to look at the clinical and cost-effectiveness of non-
invasive imaging in the diagnosis and management of
angina. To the best of the authors’ knowledge there has
been no comparable outcomes trial published on this
scale evaluating three independent non-invasive ‘gate-
keeper’ modalities versus initial angiography in stable
chest pain. The trial is also unusual in the length of pro-
spective follow-up extending to 6 years for mortality
outcomes.
We have demonstrated that use of any one of stress
CMR, stress ECHO or stress SPECT as the initial test for
a stable chest pain patient leads to non-inferior out-
comes in quality of life and cost-utility compared with
patients randomised to upfront invasive CA. Typically,
non-invasive tests perform well in low-risk populations
because of a negative predictive value which is usually
better than the positive predictive value. However, the
patient risk proﬁle was relatively high in our study, and
despite this there was no signiﬁcant difference between
an initial functional or anatomic approach.
There are several reasons why initial angiography may
not have led to clear beneﬁt in our study. First, although
angiography has stood at the heart of the diagnostic
chest pain pathway, the traditional binary cut-off values
of 50% or 70% stenosis by visual estimation were shown
in the FAME study to bear little relation to the true
physiological signiﬁcance of luminal narrowing.22
Second, data from various countries suggest that not
only is CA often inappropriate when formally rated by
expert observers23 24 but that disparate national or
regional rates of angiography do not translate into clear
mortality beneﬁts between countries25–28 and on occa-
sion may even demonstrate an inverse relationship.29
Contemporary US data from approximately 500 000 PCI
procedures collected prospectively in the National
Cardiovascular Data Registry demonstrated that, of
145 000 elective PCI cases, roughly 12% were judged
inappropriate. Furthermore, the rate of inappropriate
elective PCI between hospital sites ranged from 0% to
Figure 2 Kaplan-Meier survival estimates according to initial
modality of diagnosis.
Table 2 Cost-effectiveness summaries to 3 years postrandomisation
Angiography
(n=222)
SPECT
(n=224)
Cardiac MRI
(n=226)
Stress ECHO
(n=226)
HR for death Baseline 0.99 2.60 1.42
(95% CI) (0.35 to 2.85) (1.09 to 6.22) (0.54 to 3.74)
Mean survival (years) 2.96 2.95 2.90 2.94
(95% CI) (2.92 to 2.99) (2.90 to 2.99) (2.83 to 2.95) (2.89 to 2.97)
Mean difference vs CA − −0.01 −0.06 −0.02
(95% CI) − (−0.07 to 0.05) (−0.14 to 0.01) (−0.08 to 0.04)
Mean QALYs 2.24 2.27 2.18 2.27
(95% CI) (2.16 to 2.31) (2.20 to 2.33) (2.11 to 2.25) (2.19 to 2.33)
Mean difference vs CA − 0.03 −0.05 0.03
(95% CI) − (−5.21 to 1.38) (−5.21 to 1.38) (−3.04 to 4.21)
Mean discounted costs (£) 5243 4644 4947 5530
(95% CI) (4282 to 6461) (4194 to 5126) (4480 to 5431) (4857 to 6262)
Mean difference vs CA − −599 −296 287
(95% CI) (−1901 to 503) (−1603 to 824) (−1109 to 1537)
Probability cost-effective at £20K per QALY − 0.82 0.29 0.55
Probability cost-effective at £30K per QALY − 0.79 0.25 0.59
CA, coronary angiography; SPECT, single photon emission CT; QALYs, quality-adjusted life-years.
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55% suggesting signiﬁcant variability in practice.30 The
data suggest that a better way of selecting patients for
invasive investigation is needed.
Ischaemia-driven revascularisation has been shown to
be of beneﬁt in a number of trials, most recently in the
FAME study in which an invasive method of measuring
the ﬂow reserve of the microcirculation (Fractional Flow
Reserve, FFR) was used to allocate patients to interven-
tion or observation versus a clinical decision on interven-
tion based on angiography alone.31 At 2 years of
follow-up there were clear survival and MACE beneﬁts to
the FFR-based approach.
The ACRE study reported that, up to 6 years after
diagnosis, medical management was a more cost-
effective strategy for angina compared with PCI.32 The
lack of evidence for survival from revascularisation was
also seen in the COURAGE trial.4 Critics have suggested
this may be because randomisation to PCI versus
optimal medical therapy was made after CA had been
performed, potentially leading to a recruitment bias of
patients with less severe disease. In the CECaT trial this
bias was avoided by randomisation to a management
strategy deﬁned by the non-invasive test result for each
of the three functional arms of the trial. In a relatively
high-risk population, we demonstrated no clinically sig-
niﬁcant survival or economic detriment from using non-
invasive imaging as a gate-keeper to catheterisation.
Similarly, quality of life was not signiﬁcantly different
across all four groups and these differences extended to
a warranty period of at least 3 years.
We did observe a marginal decrease in survival in the
CMR arm. The reasons for the difference are unclear but
do not relate to patient characteristics or management
with CABG or PCI. Although statistically signiﬁcant, the
mean survival difference from the other groups was only
4 weeks over 3 years and is unlikely to be clinically mean-
ingful. Since recent work has established a strong corres-
pondence between FFR measurements and stress CMR
perfusion indices it would be surprising if CMR were
genuinely inferior to other modalities for risk stratiﬁca-
tion.33 Indeed several recent publications have high-
lighted the incremental prognostic data (above that
obtained from clinical variables) derived from several
thousand perfusion CMR studies.34 35
Given the recent publication of the CEMARC trial36 in
which a clear diagnostic superiority was demonstrated
for stress CMR over SPECT, it is interesting that our data
nonetheless show an equivalence in functional health
status between those randomised to SPECT versus CMR
in the CECaT trial. The implication may be that
although CMR detects the presence of any ischaemia
with a greater sensitivity it is the overall burden of
Table 3 Summary adverse events during initial 18 months of follow-up*
Adverse event
Angiography
(n=222)
SPECT
(n=224)
Cardiac MRI
(n=226)
Stress ECHO
(n=226)
Total adverse events 38 34 44 62
Chest pain (not myocardial infarction) 21 20 28 35
Angina 7 5 4 3
Myocardial infarction 2 0 3 6
*Note that beyond this time only events that required hospital admission were recorded.
SPECT, single photon emission CT.
Table 4 Summary of the frequency of use of the main resource use elements during follow-up of up to 3 years
(excluding initial diagnostic test)
Resource use (unit cost)
Angiography
(n=222)
SPECT
(n=224)
Cardiac MRI
(n=226)
Stress ECHO
(n=226)
CABG (£7195) 28 33 28 34
PCI (£3660) 57 46 60 62
Other hospital admission (£467/day) 36 29 28 53
Angiography (£625) 12 183 175 181
SPECT (£405) 16 3 3 6
Cardiac MRI (£565) 5 5 12 5
Echocardiography (£435) 30 17 24 18
PET scan (£842) 0 3 0 1
Preadmission clinic (£85) 22 21 27 24
Follow-up clinic (£85) 19 22 31 21
Outpatient visits (£143) 247 270 300 284
*Cardiac drugs were also included but are not shown here due to many different combinations of drugs and doses prescribed.
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PET, positron emission tomography; SPECT, single photon
emission CT.
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ischaemia that alters a patient’s prognosis. As such, it
has not yet been demonstrated that the higher diagnos-
tic accuracy of CMR translates into better long-term
patient outcomes—a fact acknowledged by Greenwood37
subsequent to CEMARC’s publication. In this context
the CECaT nuclear results are congruent with numerous
past publications and reconﬁrm the reassuring warranty
period of a normal SPECT study.
Cost-effectiveness
There was no signiﬁcant difference in cost-effectiveness
between the angiography-as-default group and the non-
invasive test groups up to 3 years, perhaps relating to the
higher-than-anticipated rate of referral for angiography
after negative functional tests. Protocol deviation of this
kind is not infrequent in trials of non-invasive technol-
ogy. In the recent PARR-2 study of patients undergoing
ﬂuorodeoxyglucose positron emission tomography for
the assessment of viability, roughly 25% of the study
population did not adhere to the protocol.38 The will-
ingness of a cardiologist to defer referral for CA in the
face of a normal non-invasive study may in part reﬂect
individual prejudices and job description (interventional
vs non-invasive) as demonstrated in a recent survey of
cardiology attitudes39 and was also reﬂected in our own
data.
In CECaT, 20–25% of patients receiving a non-invasive
test did not go on to have angiography. A proportion of
the additional cost in the non-invasive arms related to
angiography and PCI in the patients with a negative test,
although only very few subsequently required CABG—a
robust marker of signiﬁcant disease—during follow-up.
This readiness to employ PCI in a group in whom the
indication/beneﬁt is debatable was also seen in the
ACRE trial32 and reﬂects understandable clinical
response to uncertainty but also the easy access to PCI
in healthcare systems without barriers to self-referral.40
Similarly, studies from the USA have demonstrated a
Figure 3 Quality of life assessed by EQ5D over time.
Figure 4 Bootstrapped
estimates of the joint distribution
of mean cost-difference against
mean quality-adjusted life-year
difference up to 3-years
postrandomisation.
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greater willingness to use CA when available ‘on site’
as is increasingly seen even in small-to-medium sized
hospitals.41–43
Cost-effectiveness of each non-invasive technique
Nuclear myocardial perfusion imaging
The END study used propensity matching to compare a
large cohort of patients referred for either gate-keeper
myocardial perfusion imaging or upfront angiography—
this non-randomised study demonstrated a signiﬁcant
cost-reduction in the nuclear arm.44 In contrast to this
and other work45–47 we were unable to show a signiﬁcant
difference in cost-effectiveness in our own study. To
some extent this reﬂected the participating physician
bias towards angiography during the period of trial
recruitment (2001–2006) with many patients referred
for angiography despite normal perfusion studies. This
continues in the contemporary era with Chan et al30
demonstrating that almost 80% of Delphi-adjudicated
inappropriate elective PCIs were performed following
either low-risk ischaemia imaging in mildly symptomatic
patients or intermediate risk imaging in entirely asymp-
tomatic patients.
In the CECaT study, when PCI was performed despite
a negative initial non-invasive test, this occurred because
subsequent angiography indicated ‘signiﬁcant’ stenosis.
This was a clinical judgment based on ‘eyeball assess-
ment’ of lesion severity as has been reported in clinical
trials with angiographic end points.48 However, the sever-
ity and functional signiﬁcance of many stenoses may be
over-called, even by quantitative assessment, when com-
pared with the physiological assessment of fractional
ﬂow reserve across the lesion.49 50 Further improvement
in cost-effectiveness could likely have been achieved in
the nuclear arm of the trial. Our post-trial practice is to
perform the stress SPECT ﬁrst—and if this is negative—
cancel the rest test, likely augmenting the relative cost-
effectiveness of SPECT.51
CMR
There are relatively few data available regarding the cost-
effectiveness of CMR. One recent mathematical model-
ling study estimated that CMR likely has greater cost-
effectiveness/utility compared with SPECT despite
greater base case cost of the former.52 The economic
superiority of CMR was also recently described by the
CEMARC group, although interestingly the base case
costs employed for CMR and SPECT in their analysis dif-
fered by only a few pounds. Their own sensitivity analysis
in fact demonstrated that if the costs of the two tests
varied by more than 100 pounds (which was the case in
our study) then in fact—as we found—SPECT became
the dominant strategy in a low-to-intermediate risk
population.53
Stress ECHO
Stress echocardiography may be a more cost-effective
strategy than angiography for men aged 50–60 with CAD
prevalence of 50%.47 54 There is also some evidence that
stress ECHO is more cost-effective than SPECT as an
initial test,55 56 especially in women with suspected
CAD.57 A similar beneﬁt was not seen in our study prob-
ably because of the high disease prevalence in our popu-
lation. The lack of superiority of either stress
echocardiography or a combined strategy of exercise
testing and stress ECHO compared with upfront cath-
eterisation was also evident in a recent Polish study of
600 patients with a similar age, gender and disease
prevalence to our own study population.58
Taken overall, our data clearly demonstrate a limited
future role for cost-effective non-invasive imaging if
referring physicians are not willing to accept a negative
result as ground truth. This might be interpreted as
reﬂecting a need for greater physician education since
we showed a clear difference in onward referral rates for
angiography after a negative test between interventional
and non-invasive cardiologists.
Clinical effectiveness
We demonstrated that SPECT can obviate the need for
CA for a signiﬁcant number of patients without any clin-
ical detriment. In the stress ECHO group clinical out-
comes were also comparable to the angiography
subgroup at 18 months. The CMR group had statistically
marginally poorer survival and this follows our earlier
ﬁnding that CMR patients had signiﬁcantly worse exer-
cise tolerance at 18 months after randomisation.10 This
is difﬁcult to explain on the basis of Pryor risk score or
other baseline clinical variables. However, the mean dif-
ference in survival between the CMR arm and the other
groups was only 4 weeks and thus of marginal clinical
Figure 5 Estimated probability of being cost-effective
compared with angiography alone against the amount (£)
a health provider is willing to pay for one additional
quality-adjusted life-year.
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signiﬁcance. More importantly, the CMR group were not
otherwise disadvantaged—compared with the angio-
graphic control group—with respect to major adverse
events, other resource use, or quality of life.
Limitations
This study was carried out in a single specialist cardio-
thoracic centre with a signiﬁcant proportion of high
risk, predominantly white European, male patients.
Those eligible who refused the trial were older and were
more likely to be women.
Survival data from the national registry did not
include cause of death so that deaths due to cardiovascu-
lar causes could not be reported separately.
The trial completed recruitment in 2004 and we used
the technology that was available to us at the onset of
the trial. At that time, we were not able to use attenu-
ation correction for SPECT imaging; however this was
also not used in the most recent CEMARC trial.36
Similarly, we performed our CMR examinations in a
mobile facility on a 1.5 T scanner with only modest
coil technology and limited temporal and anatomic
coverage that would compare unfavourably with the 3 T
whole heart high-resolution perfusion studies available
today.
The trial aimed to reﬂect the strategy of using non-
invasive imaging as a gateway to angiography in contem-
porary clinical practice. The test results were considered in
conjunction with other information available at the
time. Thus it was not the aim to formally assess diagnos-
tic accuracy of the non-invasive tests in this context. This
trial-based study was limited to 3 year cost-effectiveness
follow-up—longer-term economic models would provide
lifetime estimates of the cost-effectiveness of the non-
invasive strategies and could include advances in
imaging technology.
Table 5 Cost-effectiveness summaries for patients managed by interventional cardiologists to 3 years postrandomisation
Angiography
(n=73)
SPECT
(n=96)
Cardiac
MRI (n=93)
Stress
ECHO (n=98)
Mean survival (years) 2.96 2.97 2.89 2.96
(95% CI) (2.91 to 2.98) (2.93 to 3.00) (2.80 to 2.97) (2.90 to 2.98)
Mean difference vs CA − 0.01 −0.07 0
(95% CI) − (−0.05 to 0.07) (−0.17 to 0.02) (−0.07 to 0.05)
Mean QALYs 2.25 2.29 2.21 2.2
(95% CI) (2.14 to 2.36) (2.19 to 2.38) (2.10 to 2.32) (2.10 to 2.29)
Mean difference vs CA − 0.03 −0.04 −0.06
(95% CI) − (−5.31 to 2.30) (−4.96 to 2.41) (−3.06 to 6.42)
Mean discounted costs (£) 5754 5205 5307 6329
(95% CI) (4651 to 6941) (4475 to 5979) (4610 to 6032) (5120 to 7713)
Mean difference vs CA − −549 −447 574
(95% CI) (−1973 to 799) (−1841 to 897) (−1097 to 2262)
Probability cost-effective at £20K per QALY 0.72 0.42 0.20
Probability cost-effective at £30K per QALY 0.70 0.39 0.21
CA, coronary angiography; SPECT, single photon emission CT; QALYs, quality-adjusted life-years.
Table 6 Cost-effectiveness summaries for patients managed by non-interventional cardiologists to 3 years
postrandomisation
Angiography
(n=149)
SPECT
(n=128)
Cardiac MRI
(n=133)
Stress ECHO
(n=128)
Mean survival (years) 2.95 2.93 2.9 2.92
(95% CI) (2.89 to 2.99) (2.85 to 2.98) (2.81 to 2.97) (2.85 to 2.98)
Mean difference vs CA − −0.02 −0.05 −0.03
(95% CI) − (−0.11 to 0.06) (−0.15 to 0.04) (−0.11 to 0.05)
Mean QALYs 2.23 2.25 2.17 2.31
(95% CI) (2.14 to 2.31) (2.16 to 2.33) (2.07 to 2.26) (2.22 to 2.40)
Mean difference vs CA − 0.02 −0.06 0.09
(95% CI) − (−6.92 to 1.90) (−5.50 to 3.45) (−5.45 to 3.71)
Mean discounted costs (£) 4936 4216 4723 4780
(95% CI) (3681 to 6665) (3635 to 4799) (4068 to 5381) (4136 to 5467)
Mean difference vs CA − −719 −212 −156
(95% CI) (−2527 to 695) (−2007 to 1258) (−1990 to 1353)
Probability cost-effective at £20K per QALY 0.75 0.29 0.85
Probability cost-effective at £30K per QALY 0.72 0.27 0.86
CA, coronary angiography; SPECT, single photon emission CT; QALYs, quality-adjusted life-years.
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Conclusions
We have demonstrated in the CECaT trial that stress
ECHO, stress CMR and stress SPECT may each be used
to defer invasive CA without clinical detriment or signiﬁ-
cant excess costs in an outpatient population with stable
chest pain.
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